Reasons for early abacavir discontinuation in HIV-infected patients

Annals of Pharmacotherapy

Volumn 37, Issue 10, 2003, Pages 1392-1397

  Peyriere, Hélène ^a   Guillemin, Valérie ^b   Lotthe, Anne ^b   Baillat, Vincent ^b   Fabre, Jacqueline ^b   Favier, Carine ^b   Atoui, Nadine ^b   Hansel, Sylvie ^a,c   Hillaire Buys, Dominique ^a   Reynes, Jacques ^b  

^a LAPEYRONIE HOSPITAL   (France)

^b GUI DE CHAULIAC HOSPITAL   (France)

^c College of Pharmacy ^*  (France)

Author keywords

Abacavir; Early discontinuation; Hypersensitivity reaction

Indexed keywords

ABACAVIR; COTRIMOXAZOLE; DIDANOSINE; EFAVIRENZ; FLUCONAZOLE; FLUCYTOSINE; INDINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; ASTHENIA; BONE DISEASE; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIPODYSTROPHY; LIVER DISEASE; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MUSCLE DISEASE; NEUROTOXICITY; PANCREAS DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN DISEASE; TOXICITY; TREATMENT OUTCOME;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; FEMALE; FRANCE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 10744226745     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C523     Document Type: Article

References (15)

1. Hervey PS, Perry CM. Abacavir: a review of its clinical potential in patients with HIV infection. Drugs 2000;60:447-79.
2. Hetherington S. McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transciptase inhibitor abacavir. Clin Ther 2001;23:1603-14.
3. Clay PG, Rathbun RC, Slater LN. Management protocol for abacavir-related hypersensitivity reaction. Ann Pharmacother 2000;34:247-9. DOI 10.1345/aph. 19107
4. Hewitt RG. Abacavir hypersensitivity reaction. Clin Infect Dis 2002;34: 1137-42.
5. Escaut L, Liotier JY, Albengres E, Cheminot N, Vittecocq D. Abacavir rechallenge has to be avoided in case of hypersensitivity reaction. AIDS 1999;13:1419-20.
6. Edde Loeliger A, Steel H, McGuirk S, Powell WS, Hetherington SV. The abacavir hypersensitivity reaction and interruptions in therapy (letter). AIDS 2001;15:1325.
7. Frissen P, de Vries J, Weigel H, Brinkman K. Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity. AIDS 2001;15:289-92.
8. Begaud B, Evreux JC, Jouglard J, Lagier G. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Thérapie 1985;40:111-8.
9. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993;269:729-30.
10. Léautez S, Esnault J, Billaud E, Ferre V, Raffi F. Efficacy and tolerance of abacavir-containing antiretroviral regimens in a cohort of 145 HIV+ patients (abstract 239). Presented at: 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, July 8-11, 2001.
11. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLAB*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002;359:727-32.
12. Van Roon E, Verzijl J, Juttmann J, Lenderink AW, Blans MJ, Egberts AC. Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:290-4.
13. D'Arminio Monforte A, Lepri A, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS 2000;14:499-507.
14. Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Lepri AC, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 2001;15:185-94.
15. Bourezane Y, Salard D, Hoen B, Vandel S, Drobacheff C, Laurent R. DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy. Clin Infect Dis 1998;27:1321-2.